Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors - Shi, Yuhao; McKenery, Amber; Dolan, Melissa; Mastri, Michalis; Hill, James W; Dommer, Adam; Benzekry, Sebastien; Long, Mark; Abrams, Scott I; Puzanov, Igor; Ebos, John M L (EMBO reports, 2025)
Keywords: Animals; B7-H1 Antigen - antagonists & inhibitors; B7-H1 Antigen - genetics; B7-H1 Antigen - metabolism; Biomedical and Life Sciences; Cancer; Cell Line, Tumor; Drug Resistance, Neoplasm; EMBO03; EMBO19; EMBO37; Humans; Immune Checkpoint Inhibitors - pharmacology; Interferon Type I - metabolism; Life Sciences; Mice; Neoplasms - drug therapy; Neoplasms - immunology; Neoplasms - metabolism; Neoplasms - pathology; Signal Transduction - drug effects; Resistance; IFN; PD-L1; Immune-checkpoint; Secretome